Hello, and welcome to the Allogene Therapeutics First Quarter 2024 Conference Call. At this time, all participants are in a listen-only mode. After the speakers' presentation, there will be a question-and-answer session. Please be aware that today's conference is being recorded. We ask that you limit yourself to one question only. I would now like to turn the conference over to Christine Cassiano, Chief Corporate Affairs and Brand Strategy Officer. You may begin.

Thank you, operator, and welcome to all who have joined this call. After the market close today, Allogene issued a press release that provides a business update and financial results for the first quarter of 2024. This press release and today's webcast are both available on our website. Following our prepared remarks, we will host a Q&A session. We ask you to limit your questions to one per person as we will keep this call to an hour and do our best to get to as many questions as possible. Joining me today are Dr. David Chang, President and Chief Executive Officer; Dr. Zachary Roberts, Executive Vice President of Research & Development and Chief Medical Officer; and Geoff Parker, Chief Financial Officer. During today's call, we will be making certain forward-looking statements. These may include statements regarding the success and timing of our ongoing and planned clinical trials, data presentations, regulatory filings, future research and development efforts, manufacturing capabilities, the safety and efficacy of our product candidates, expanded cema-cel development, and 2024 financial guidance among other things. These forward-looking statements are based on current information, assumptions, and expectations that are subject to change. A description of potential risks can be found in our press release and latest SEC disclosure documents. You are cautioned not to place undue reliance on these forward-looking statements and Allogene disclaims any obligation to update these statements. I'll now turn the call over to David.

Thank you, Christine, and welcome to those on the call today. We are excited to speak with you today to discuss how we have continued to strengthen our allogeneic CAR T leadership position on every front. In January, we announced our pivot to focus development on differentiated and competitive programs that are importantly designed to address unmet needs. In doing so, our future market opportunity dramatically increased. In large B cell lymphoma alone, moving from the later line into the front line consolidation meant that the U.S. market opportunity grew from approximately $500 million to more than $6 billion. That change meant something significant. It was time to extend our territory rights to include all of the European Union and the U.K. from Servier. We are excited to have executed that vision, and Geoff will provide more details on that agreement on this call. Our team is making great progress in four core programs we outlined in January. We are very proud of the transformative potential of our pivotal ALPHA3 trial with cema-cel, which is expected to readout in 2026, leading to potential BLA submission in 2027. This trial is designed to embed cema-cel as a part of a curative first line regimen and has the potential to change the standard of care for patients with large B cell lymphoma. The last point being something I want to emphasize as that is very rare in oncology. Our cema-cel program could also set a new standard for what a CAR T can achieve in relapse/refractory chronic lymphocytic leukemia, or CLL. Differentiation is critical across our core programs. We declared a move into the autoimmune space with the goal of resetting the immune system with a single infusion. ALLO-329, our next-generation CD19/CD70 dual CAR, which incorporates our Dagger technology and CRISPR-based gene editing for site-specific integration is designed to meet the unique needs of patients with autoimmune disease. Our Dagger technology provides a potential path to reducing or eliminating lymphodepletion, which we believe may create more development and commercial opportunities for ALLO-329 in autoimmune indications. Our ALLO-316 program could be the first to demonstrate the unique potential of a CAR T in solid tumors. We believe our $15 million California Institute for Regenerative Medicine grant awarded last month validates the remarkable enrolls made in our TRAVERSE trial and the therapeutic potential ALLO-316 has for patients with advanced renal cell carcinoma. This grant funds the completion of the Phase 1 trial. We are grateful for the recognition from the CIRM reviewers of the potential for ALLO-316 to make a difference for patients. Lastly, we are pleased to have strengthened our cash runway to extend into the third quarter of 2026. I am very excited by the caliber of investors who participated in this financing and their demonstrated commitment to our mission. In addition, members of our Board and Executive Management, including our Executive Chair, Arie Belldegrun, Geoff, our CFO, and I have further demonstrated our commitment to Allogene by participating in this offering. Understandably, many investors are focused on milestones related to our pivotal ALPHA3 trial, but it is essential to appreciate the multitude of inflection points across all our programs. Later in the call, Zach will review the development milestones across all four core programs. We will continue to focus all our resources on advancing these core programs and believe we are well-positioned to change the CAR T treatment landscape to benefit patients. I'd like to turn the call over to Geoff to review our announcements today.

Thank you, David. Let me first start with the press release we just issued announcing our $110 million equity financing. We know that our cash runway is critical. When we announced our pivot earlier this year, we had strong renewed interest from top-tier institutional investors and mutual funds. Based on those conversations, we made the strategic decision to pursue a financing that builds our cash reserves and extends our runway into the second half of 2026, during which time we expect to have the interim efficacy analysis and to complete enrollment of the ALPHA3 trial. In addition, this financing importantly reshapes our investor base. The quality of the investors who are part of this raise, including five of the largest institutional investors in mutual funds, leading healthcare specialists, and select members of our Board of Directors and management team, is indicative of the depth of interest in our allogeneic CAR T strategy. And we look forward to validating their belief in Allogene as we execute on our goals. Another example that underscores our belief in our programs is our just-completed amendment to our agreement with Servier. You may recall that when Allogene was formed, we had only the U.S. rights for cema-cel under the Servier agreement. The timing for us to obtain these rights now versus a few years ago when they first became available was driven by two important factors. First, the dramatically increased market opportunity now with LBCL front line consolidation and CLL. And two, the ability to establish future strategic partnerships. Let me start with the market opportunity. Our lead trial for cema-cel before our announcement in January was in third line LBCL. At that time, we estimated a market opportunity of approximately $500 million in that indication. After our announced pivot for this program into first line consolidation in LBCL and relapsed/refractory CLL, our new market opportunity dramatically increased to more than $6 billion in the United States. What we've just negotiated with Servier significantly expands our rights by adding the EU member states and the U.K. to further increase our market opportunity to more than $9.5 billion, in turn, increasing the potential future revenue opportunity for cema-cel by more than 50%. We now also have the option to add Japan and China at no additional cost when we can demonstrate the resources required to advance cema-cel in that region. This brings me to point number two, future strategic partnerships. Given the market opportunity and excitement for cema-cel in community cancer centers, you might surmise growing interest in a potential partnership. And this excitement will only grow over the next six to 12 months as the program is de-risked. We control the only clinically-validated allogeneic CD19 CAR T product positioned to transform how and where CAR Ts are used in heme malignancies. With this agreement, we have consolidated rights in key commercial markets, making a potential partnership far more attractive. Importantly, we did so at a cost that is minimal compared to the market opportunity for cema-cel. The financial terms are quite favorable for Allogene, given the expanded geography. We've agreed to increase our overall regulatory milestones by $25 million, and our obligation on commercial milestones increases by $10 million. Our royalty burden increases modestly but remains effectively the same in the low-tens to mid-teens in the U.S., and we have a flat 10% royalty in the EU territory and the U.K. Our royalty would also be 10% if we pursue our rights in Japan and China. Let me now turn to our financial update for the first quarter and the impact of our just announced financing. Our cash balance as of the end of Q1 2024 was $397.3 million in cash, cash equivalents, and investments. Pro forma for the financing we announced today, our cash balance will increase to approximately $500 million. Our cash runway now extends into the second half of 2026. Q1 2024 research and development expenses were $52.3 million, which includes $3.8 million in expenses associated with non-cash stock-based compensation. General and administrative expenses in Q1 were $17.3 million, which includes $8.1 million of non-cash stock-based compensation expense. For Q1 2024, our net loss was $65 million or $0.38 per share, including non-cash stock-based compensation expense of $11.9 million in total. For 2024, we now expect a cash burn of approximately $200 million, a slight increase of $10 million to our prior guidance due to the timing impact of our revised milestone obligations to Servier, offset by expected proceeds from our $15 million CIRM grant related to our ALLO-316 program. We expect full year 2024 GAAP operating expenses to be approximately $300 million, which includes estimated non-cash stock-based compensation expense of approximately $60 million. This guidance excludes any impact from potential business development activities. I'll now turn the call over to Zach, who will focus his comments on key milestones in our core development programs.

Thank you, Geoff. As I review key development milestones, I'd like to turn your attention to the new corporate presentation posted in the Investor Relations section of our website. Approximately one-third of LBCL patients who initially respond to R-CHOP will likely relapse. Unfortunately, until recently, there has been no way to know which patients would be cured by front line R-CHOP versus those who would experience a disease recurrence and require treatment in second line or beyond. Because of this inability to give an accurate prognosis after the conclusion of front line treatment, the standard of care after front line treatment has for decades been to watch and wait for the disease to relapse. In January, we announced a partnership with Foresight Diagnostics, who is developing a novel and potentially practice-changing test for minimal residual disease, or MRD. This investigational test, when administered following completion of front line treatment for LBCL, has the potential to offer a highly-accurate prediction of future disease relapses. We believe this test could provide us with the ability to identify those patients who are most likely to relapse after front line and to take action to potentially prevent that relapse, namely a consolidation dose of cema-cel delivered immediately following the discovery of persistent MRD. ALPHA3 is designed with the specific attributes of cema-cel in mind. First and foremost, it maximizes the allogeneic advantages of cema-cel as a one-time, off-the-shelf treatment that can be administered immediately upon discovery of MRD following six cycles of R-CHOP. If ALPHA3 is successful, cema-cel could become the standard seventh cycle of front line treatment available to all eligible patients with MRD. Additionally, ALPHA3 builds on the growing understanding that administering CAR T therapies to patients with low disease burden can improve safety and efficacy outcomes. Cema-cel's Phase 1 safety profile with low rates of CRS and ICANS already permits its use in the outpatient setting in relapse/refractory patients and may further improve in patients with no radiological evidence of disease. The outcome of this pivotal trial could allow cema-cel to be embedded in the front line setting where autologous therapies are far less feasible. Consolidating response following an MRD positive result post-R-CHOP requires immediate and definitive action to prevent an impending relapse. Relapses tend to happen quickly after completion of R-CHOP, in many cases within weeks to a few months, making the speed to treatment a critical factor in the success of a consolidation strategy like ALPHA3. Cema-cel treatment could begin within days following MRD test results. As we have seen, autologous CAR Ts have had difficulty penetrating community cancer centers and accessing earlier line patients. Use of cema-cel won't rely on the complex logistics that have hindered CAR T adoption, nor will there be a reliance on referrals as the intent is for CAR T to be available in these community cancer centers. These doctors have been waiting for an allogeneic-like cema-cel to use CAR T in their centers. We believe autologous CAR Ts, bispecifics, or any other treatment modality cannot reproduce the differentiated attributes of cema-cel. You can see what this journey looks like across modalities on Slide 8. Slide 14 provides greater granularity regarding what to expect during the ALPHA3 pivotal trial. Startup activities for ALPHA3 are well underway and are nearing completion at several sites. In fact, we have completed the selection of nearly all clinical trial sites that include community-based cancer centers. The study will randomize approximately 240 patients who are MRD positive at the end of front line therapy to either consolidation with cema-cel or the current standard of care, which is observation with serial clinic visits, blood draws, and CT scans. With a primary endpoint of event-free survival, the design will initially include two treatment arms that differ in the lymphodepletion regimen used. One arm will feature standard fludarabine and cyclophosphamide plus ALLO-647, and the other, fludarabine and cyclophosphamide alone without ALLO-647. The first indication of how the trial is proceeding will be when we announce the selection of the lymphodepletion regimen we will continue to the end of the trial. That announcement is expected in mid-2025. The next study milestones will come less than a year later. First, we expect to complete enrollment in the first half of 2026. And second, because the prognosis of patients who are MRD positive at the end of front line therapy is quite poor, study events are expected to come in quickly. So, we expect to perform efficacy analyses in 2026 as well. This will include an independent data safety monitoring board interim efficacy analysis in the first half of 2026 and the data readout of the primary EFS analysis in the second half of 2026. If the trial is successful, we expect to follow these data readouts with a biologic license application, or BLA, submission targeted for 2027. The outcome of this pivotal trial could allow cema-cel to improve cure rates and become the only treatment approved for the consolidation of front line treatment, potentially reducing the need for CAR T in the later lines and simplifying the decision for front line treatment. Knowing an effective consolidation option exists could abrogate the need for complex regimens of five, six, or even more agents in newly diagnosed patients. On Slide 19, we briefly look at the next key milestones for the ALPHA2 CLL cohort. There is strong scientific rationale to believe that an AlloCAR T product derived from healthy donor cells could create a clinically meaningful advance for these late-stage patients with a one-time dose and simpler administration and logistics. The Phase 1 cohort will include 12 patients treated with cema-cel and is now enrolling patients. We expect to complete Phase 1 trial enrollment and have an initial data readout by the end of this year. Based on the outcome of this trial, we would expect to move into a pivotal Phase 2 trial in 2025. The bar for this trial is modest, given that an autologous CAR T therapy was recently approved with an overall response rate of 45% and a complete response rate of 20% in patients who received infusions at the target dose. Considering all those who underwent leukapheresis, the response rate and the complete response rate fell to 37% and 14%, respectively. Importantly for an off-the-shelf CAR T product candidate like cema-cel, virtually all enrolled patients who have met all trial criteria are expected to receive infusions. I want to turn your attention to Slide 27 and our autoimmune program next. ALLO-329 is our wholly-owned next-generation site-specific integration-based dual targeting CD19/CD70 AlloCAR T. Our design is centered on both scalability and reducing or even eliminating lymphodepletion, which we believe is absolutely critical for rapid clinical development and future commercial success. We are currently working on our IND-enabling manufacturing process and analytic assay development. We expect to file an IND in Q1 2025 and begin enrolling that trial in the first half of 2025. As a result, we expect to have proof of concept in this trial by the end of 2025. We recognize that highest clinical proof of concept is in lupus, but as we have noted earlier, we also recognize the importance of differentiation, so we are considering other indications with unmet need. Lastly, Slide 30 reviews our Phase 1 TRAVERSE trial timeline for ALLO-316. This quarter, we plan to detail what we believe will be a fundamental discovery, the algorithm that may mitigate the treatment-associated hyperinflammatory response without compromising the CAR T function needed to eradicate solid tumors. The manuscript is currently undergoing peer review. A Phase 1 data update from approximately 20 patients with CD70-positive renal cell carcinoma is planned by year-end 2024. In totality, and as shown on Slide 32, we have meaningful data flow between now and through 2026 that will demonstrate the potential of our programs. We look forward to answering any additional questions you have on our pipeline during the Q&A. We'll now open the call for questions.

Thank you. Our first question comes from the line of Michael Yee with Jefferies. Your line is open.

Hey, guys. Congrats on all the progress, and I guess consolidation of everything, I think, it speaks to the bullish nature of how you guys are looking at things. I guess, I know you want to keep it to one question, I guess it's a two-parter. On the Phase 3 that you're enrolling in consolidation, can you explain your visibility on enrollment sites, patient numbers? I know that was always a question for the later line studies, but also would be a meaningful question for these studies given some of the sites we've talked to are still trying to understand the protocol and the design of the study as you'd be breaking new ground. So, I want to understand your confidence on that. And then part two of that is, what is the difference between the interim analysis and the full primary EFS analysis? Thank you.

Thanks, Michael. This is Zach. Good questions. Regarding the first question about feasibility, I can share that there has been significant interest in this program from both academic and community-based oncology centers. We expect to have about 50 clinical trial sites open in the United States, which will include a mix of community practices and tertiary care academic centers. Almost all of these sites have been selected, and we are on track to activate our first group of sites by the middle of this year to allow for trial enrollment. The enthusiasm from these clinical trial sites has been very high. Your second question about the difference between the interim and primary analyses in 2026 relates to the number of EFS events we will assess at those points.

Thank you. Please stand by for our next question. Our next question comes from the line of Tyler Van Buren with TD Cowen. Your line is open.

Hey, guys. Thanks for that, and congrats on all the progress. So, I believe the likelihood of the ALPHA3 trial succeeding is super high, frankly. So, do patients appreciate the risk of being MRD positive after R-CHOP? Or why wouldn't they choose to undergo this therapy and enroll in the trial?

Thanks, Tyler. So, I don't think that the concept of MRD has made its way into sort of the general consciousness of the patient population yet. We do think that that is coming and probably come quickly. That's not the case for the investigators who have signed up for the trial. They all see the potential for this assay and its potential ability to change practice. With respect to an individual patient and doctor conversation about whether to enroll in the study, we believe that this study will be highly attractive to the patients because they'll be looking for an MRD negative result to tell them that they're likely cured of their malignancy. Now, for those patients who are MRD positive, we also can't really understand why a patient wouldn't at that point jump at the chance to receive a dose of cema-cel in consolidation for all the reasons that we've detailed. Importantly, there are no approved therapies right now available for patients who are in remission at the end of front line but remain MRD positive. We believe that this will be a fairly significant competitive advantage for us during the enrollment and at the time of potential launch.

Thank you. Please standby for our next question. Our next question comes from the line of Salveen Richter with Goldman Sachs. Your line is open.

Good afternoon. Thanks for taking my question. Into the cema-cel data in CLL into year-end, could you just help us understand what you would view as a positive outcome here and where the clinical bar currently lies?

Thanks, Salveen. So, we think that the bar here is still quite low, as a matter of fact, and the unmet need here is only growing in this relapse/refractory CLL population. As we mentioned during the prepared remarks, a recent autologous CAR T product was approved on a fairly modest response rate and complete response rate. Importantly, we believe that the patients who derive benefit tend to do so fairly quickly following an infusion of CAR T cells. So, fast forwarding now to the end of this year, as we mentioned, we're enrolling the Phase 1 cohort now, and we expect to have that data shared at the end of this year. Now, of course, there will be limited follow-up on those patients. However, we should be able to have response rate and some modest follow-up on some of those patients at least. So, we expect that this data will be helpful for us as we're planning to make that go/no-go decision for pivotal next year.

Thank you. Please standby for our next question. Our next question comes from the line of Reni Benjamin with Citizens JMP. Your line is open.

Hey, thanks for taking the questions, and congratulations on all the progress, especially getting the rights back. And that's my question mainly. Are you ready to move forward with cema-cel commercialization in Europe by yourself, or do you really feel that this is something that must be done with a partner? And I guess just related to that in terms of manufacturing, is this something that you could do from here in the States and ship out, or do you feel that you would have to create a manufacturing facility in Europe? Thanks.

So, Ren, this is Dave Chang. Let me answer that question. We are extremely excited to gain rights to the European Union and U.K. I mean this is really big and increases the market potential of the cema-cel significantly. The two questions that you're asking, the EU, how ready we are, I mean, we just signed a deal, give us a little bit of chance. I mean, this is something that we have done in our previous experiences to place the clinical study and also prepare for regulatory filing and also for commercialization. But right now, the ink is drying, so give us a little bit of time before we outline how we plan to expand in Europe. And as Geoff has also mentioned, this is also what I believe as an opportunity for partnership, which we believe can bring a significant upside to how much and how fast we can expand the program in Europe. The second question that's a relatively simple one. I mean we have our own manufacturing facility, Cell Forge 1 across the Bay, that's the San Francisco Bay. And that facility from the beginning was designed to meet the clinical as well as the commercial regulatory requirement for both U.S. and Europe. And yes, you're absolutely right. We can manufacture the product there and ship it to Europe for clinical studies.

Thank you. Please standby for our next question. Our next question comes from the line of Luca Issi with RBC Capital. Your line is open.

Great. Thanks so much for taking my question. Congrats on the progress. Maybe a quick one for you, Zach. Can you just talk about the powering assumption in ALPHA3? I think your prior corporate deck actually flagged eight months as the expected median EFS for the control arm, but I no longer see that in your new deck. Anything to read into that? And also, how you're thinking about the median EFS for the active arm, given you actually never tested that product in that settings? Any color there much appreciated. Thanks so much.

Thanks, Luca. So, we haven't gone into details around the powering assumptions that we made for the overall study design. As you'll note, the sample sizes have remained consistent to 110 patients versus 110. As far as the timing of the EFS events on the control arm, so eight months that we had previously featured really was counting from the initiation of R-CHOP. And actually, it's probably somewhere between four to eight months, which will actually unfold in the context of the study, and that's based on a fair amount of published literature for patients treated with R-CHOP. The second question?

What we expect on the control treatment arm?

Yes, regarding what we can control for the treatment arm, this relates to the powering assumptions, which we haven’t disclosed publicly. However, we can share that our experience from the Phase 1 program indicates that patients who achieve a complete response tend to do very well and remain in that response. Additionally, there is a growing body of literature suggesting that treatment with CAR T cells at relatively low disease burdens tends to result in improved efficacy outcomes. While we don’t have direct experience with the minimal residual disease positive patient population, there is substantial evidence indicating that this approach will likely work effectively and significantly enhance event-free survival compared to the control arm.

And Luca, let me just add on by saying that this study is well powered for EFS event as well as PFS. And I would just ask you to look at the sample size, how big the study was in the second line setting of the Yescarta and Breyanzi that led to a successful outcome and essentially bringing forward a treatment that changed the practice.

Thank you. Please standby for our next question. Our next question comes from the line of Asthika with Truist. Your line is open.

Hi, guys. Thanks for taking my questions. And I'll also offer my congratulations on saving the rights of cema-cel from Servier and the financing that you just announced. I'm going to do a spin-off on Tyler's question, and I share the same enthusiasm he does as well for ALPHA3. But I'm going to also ask, given the confidence you're going to have in the active arm, what's going to compel a patient to stay on the control arm once they know that they've been on the control arm there? And then, if I can squeeze another quick one in. In CLL, how much persistence is needed? We know with LBCL upfront tumor killing is what's really important. What do we know about CLL right now, in terms of how much persistence is really needed?

Thanks, Asthika. So, coming back to the question on the patients who get randomized to the control arm, so there's a couple of reasons that they would stay on the control arm. Putting my sort of patient hat on, I think it's going to be quite reassuring for them to know that they're being followed very closely in the context of a clinical trial, at least as closely as they would be followed per standard of care, and often because the focus on getting patients into the clinic and so forth is so much higher in the context of a clinical trial, probably even closer follow-up. So, if I'm a patient knowing that I'm getting the standard of care, but I'm going to be watched like a hawk, I think we'll go a long way to reassuring patients. And then, I'll reiterate that even if those patients decide to discontinue on the clinical trial, it's not as though they can find a physician who is going to treat them for their MRD disease. They're still going to have to wait for a relapse. There are no approved therapies for patients who are in remission with LBCL currently. With the second question on CLL around persistence, I think the evidence is still developing there. And I think we have to sort of not dive too deep into that rabbit hole. We do know that these cells need to be around for a period of time. We have been able to show in the context of LBCL that our cells can stay around for quite a number of months, in some cases, six months and beyond. So, we do with our current FCA-based lymphodepletion regimen, we create a nice window of persistence for these cells to get in there and eradicate tumor.

Let me just add on that one comment, which I would like to make. Since the questions about how well this study will enroll and how the patients will behave once they are enrolled in the study. I mean, at this point, yes, we have not studied the study, but the study was designed with significant input from the KOLs, both academic-based KOLs as well as the community-based KOLs. And their opinion was unanimous about this design of the study, the randomized design as well as how to handle the control arm. So, I think in terms of how the investigators will support the conduct of the study, which we are relying a lot. Given the enthusiasm that they have expressed, that's where we have a lot of comfort level about the projections that we are making about the study enrollment cadence.

Thank you. Please standby for our next question. Our next question comes from the line of Brian Chinn with JPMorgan. Your line is open.

Hi, guys. Thanks for taking our question. On autoimmune, there's a question of whether lymphodepletion is essential in optimizing CAR T expansion. Can you tell us your perspective on the likelihood of completely eliminating lymphodepletion? What are some of the key factors in bringing that to reality? Thanks.

Yeah. Brian, let me take on that question. Again, as we have said, ALLO-329, the program that we are advancing in autoimmune, IND is planned for the Q1 of 2025. And we're hoping to get the initial proof of concept communicated by the year-end. The question of whether the lymphodepletion is needed or not, this is something that we have thought through very carefully. Looking at the data that we have from ALLO-501A, this is our CD19 allogeneic CAR T program as well as ALLO-316, which is a CD70 CAR T program, where we have treated a number of patients with renal cell carcinoma. So, combining those data together and looking at all the translational data that we have seen is very clear. When you have the Dagger technology, allogeneic CAR T cells expand remarkably well. And we know that in terms of how CAR T behaves depends very much on the expansion capability of the CAR T cells. So, that's information number one. Number two information is what we believe is necessary to reset the immune system in patients with autoimmune disorders. We do not. And also, this is the view of many KOLs as well. Nobody believes persistence is required. One common theme is the depth of the depletion initial depletion, that's important. But when we put all the information that we have together, we believe ALLO-329 will expand well. And with that, we will achieve the depletion of B cells and activated T cells, and we believe that is critical to reset the immune system.

Thank you. Please standby for our next question. Our next question comes from the line of Sami Corwin of William Blair. Your line is open.

Hey, there. Thanks for taking my question, and congrats on the progress. I was wondering if you could clarify how many of the 240 or so patients being enrolled in ALPHA3 will be enrolled initially in the three arms versus after the interim analysis and lymphodepletion selection? And then just kind of curious why you have decided not to look at MRD negativity as a secondary endpoint in that trial, just considering it does seem to be predictive of a long-term remission. Thanks.

Thanks, Sami. Those are great questions. We haven't specified the exact number of patients for the three-way randomization, but we have mentioned that the hypothesis testing for the control arm versus treatment arm will take place with approximately 110 patients in each arm. This gives an indication of how many more patients we may need to enroll. It's a small fraction of the total enrollment, and that number was chosen to ensure we have sufficient statistical power to make well-informed decisions regarding safety, efficacy, and translational outcomes, while avoiding enrolling a large number of patients who would receive an LD regimen not continued throughout the enrollment period. Regarding the secondary endpoint for MRD, we will be looking at MRD clearance as an exploratory endpoint. However, it didn't seem appropriate to make it a key secondary endpoint since we used the same test to initially select patients for enrollment. We're genuinely excited about the potential for MRD clearance as a key endpoint in clinical trials, but we believed it was best to focus on traditional endpoints like EFS for this Phase 2 trial.

Thank you. Please standby for our next question. Our next question comes from the line of Jack Allen with Baird. Your line is open.

Great. Thank you very much. Congratulations to the team on all the progress. I wanted to ask about Cell Forge 1. Are you planning to produce the material for ALPHA3 from Cell Forge 1 and ALPHA2 for the CLL patients? Also, considering ALPHA3 and the acquisition of global rights for ALLO-501A, do you see ALPHA3 potentially becoming a global study, or are you committed to running it solely in the U.S.?

Jack, both are great questions. The Cell Forge 1 is our GMP facility, and it is fully operational, producing the GMP materials necessary for us to conduct both the CLL and ALPHA3 studies. Regarding the clinical supply, we typically do not provide details on that. Can you remind us what the second question was?

Yeah. I was asking about the reacquisition of the rights. It sounds like someone has reminded you.

We have obtained rights from Servier for Europe and the U.K. We are very interested in expanding our clinical trial presence as we get ready to commercialize in these new regions. Since we just signed the deal, please stay tuned for more information about our activities in those areas in the future.

Thank you. Please standby for our next question. Our next question comes from the line of John Newman with Canaccord. Your line is open.

Hi, guys. I'd like to add my congrats on all the progress as well. I had a question about ALLO-329 in the autoimmune setting. Some of your competitors are rolling studies in the autoimmune area, but they're including dermatomyositis patients or they're running separate studies. My question is, are you considering including those patients in your study, and might there actually be an interesting filing strategy there given that it's an orphan disease? Thanks.

Thanks, John. I think I'll ask you to stay tuned for further details on the clinical development plan as we kind of get a little bit closer to the IND submission. As we mentioned in the prepared remarks, we're going to be looking carefully at the existing proof of concept out there but also looking for opportunities for differentiation in the development plan. So, please stay tuned.

And John, let me just add on, I mean ALLO-329 is a very exciting program. There's a lot of interest. And once we obtain the proof of concept, this is also a program that can expand into many different indications in the autoimmune space that includes not only the indications where CAR T has proven initial proof of concept, but also indications where the T cell component may play a bigger role. As a reminder, one of the key innovations and differentiation that we introduced into ALLO-329 is having a dual CD70/CD19. And the CD70 component has the ability to bring the Dagger biology as we have just talked about but also address the activated T cells, which we believe has a pretty important role in the pathogenesis of autoimmunity.

Thank you. Please standby for our next question. Our next question comes from the line of Kalpit Patel with B. Riley. Your line is open.

Thanks for taking my question. This relates to an earlier question, but do you think you will need multiple doses of ALLO-329 initially to achieve the significant B cell depletion we have observed with auto-CAR T therapies in autoimmune diseases, especially since you plan to lower the dose or the use of lymphodepletion?

Let me take that question. We plan to rely on a single infusion to maximize the benefit of ALLO-329.

Thank you. Please standby for our next question. Our next question comes from the line of Samantha with Citi. Your line is open.

Hi. Thanks very much for taking the questions. Just on ALLO-329, given you have the dual targeting approach, how are you thinking about the potential onset of the treatment-associated hyperinflammatory response that you've observed in the TRAVERSE study? With the diagnostic and treatment algorithm that you developed, is that applicable to the autoimmune population as well? And can you just characterize a bit how you think the side effects might be viewed by rheumatologists? Thank you.

Thank you for the question, Samantha. We have thoroughly analyzed the data from the ALLO-316 program, which shows significant cell expansion after infusion. As with any CAR T therapy, this substantial cell expansion leads to a hyperinflammatory response. This response is a key pharmacodynamic effect of ALLO-329 that we plan to utilize. To address your concerns, one approach is to avoid increasing the high cell dose. The autoimmune space is a large indication, and we consider the scalability of cell therapy to be crucial. ALLO-329, from both the manufacturing and other perspectives, can support the number of patients needed to meet the demands of the autoimmune space. Therefore, we believe that the expansion potential of ALLO-329 will enhance our capacity to advance autoimmune programs effectively.

Thank you. Please standby for our next question. Our next question comes from the line of Kelsey Goodwin with Guggenheim. Your line is open.

Hey, thanks for taking my question, and congrats on all the progress. For 316, I guess maybe could you just remind us the efficacy benchmark in RCC and what you'd need to see at the end of the year in order to advance this program further? Thank you.

Thanks, Kelsey. So the relapsed/refractory RCC outcomes are still quite poor. There's been a recent approval there. However, it didn't really make much headway in terms of response rate or durability response over existing third line agents approved here. So, we think that, that bar is still quite low. Some of the response rates somewhere around 20% is the benchmark that we're looking at from the literature. And as you recall, when we shared data back at AACR last year, we were above that with a 30% response rate in patients whose tumors were known to express CD70. So, we're pretty encouraged by that early sign of efficacy.

Thank you. Please standby for our next question. Our next question comes from the line of Laura Prendergast with Raymond James. Your line is open.

Hey, thanks for taking all the questions. One for me. Just thinking about barriers for the community center, readiness for cema-cel and MRD testing versus what you might see at the academic center, any barriers you anticipate there?

Thanks, Laura, for that question. I'll start by saying that, to the contrary, actually, what we're finding is these centers that we're approaching, these community centers, even those without hands-on CAR T experience, are extremely well equipped to run this trial. And that's because these docs have been giving bispecifics to patients now for several months for this indication, of course, bispecifics for other indications as well. And so, the toxicity profiles and the unique adverse events that T cell directed therapies share across different modalities, I think, has given both us and these docs confidence that they'll be able to handle the patients that are treated on this trial. Of course, there is another category of barrier that I think has kept these centers from jumping into CAR T over the last decade, and that is a lot of the operational and logistical barriers that they just have not been willing to undertake at their centers. Because cema-cel is off-the-shelf, it's shipped on demand, and in many cases can be administered as an outpatient, all of those logistical and operational barriers that these centers face go away. And so in fact, what we have found is actually quite an open and enthusiastic set of partners even in those who don't have direct hands-on CAR T experience.

Thank you. Please standby for our next question. Our next question comes from the line of Ben Burnett with Stifel. Your line is open.

Hi, good afternoon. This is Carolina Ibanez Ventoso on for Ben Burnett. Thank you for taking our questions. First in the ALPHA3 trial, will you do a second MRD assessment after lymphodepletion, but before administration of cema-cel? And then separately, given that ALLO-316 and ALLO-329 are based on the Dagger technology, would it be fair to look at the clinical update from the TRAVERSE trial later this year as a window for the initial safety expected with ALLO-329? Thank you.

Thank you, Carolina. Regarding your first question, we generally avoid discussing the specifics of the assessment timing in the clinical trial. However, I can say that MRD testing is not typically designed to turn negative in just five days, as the tumor is likely still present and won’t be cleared in that short time frame. Therefore, the usefulness of such an assessment would be questionable. For your second question, concerning whether the efficacy update we will share later this year from TRAVERSE will provide insights into potential efficacy or outcomes for 329, we have carefully analyzed the biology of 316 in the TRAVERSE trial while designing ALLO-329 specifically for an AID population. We have strong confidence in the Dagger biology and its ability to support effective engraftment and persistence of these cells. I won’t elaborate beyond that. It's worth noting that the requirements for cell persistence differ between AID and oncology settings. This is a dual targeting CAR, compared to a single targeting CAR. Thus, because of the significant differences in design and patient demographics, I don't believe scrutinizing the 316 results will provide us with valuable guidance for 329.

Thank you. Ladies and gentlemen, I'm showing no further questions in the queue. I would now like to turn the call back over to management for any additional comments.

Thank you, operator. We are very proud of how we continue to strengthen Allogene on all fronts and making sure we remain competitive today and in the future. We will continue to focus all our resources on advancing our core program. And with today's announced financing, we are well-positioned to extend the cash runway into important data readouts. And more importantly, we believe we are well-positioned to change the CAR T treatment landscape for the benefit of patients. Our thanks to you for joining us on the call today and our sincerest gratitude to our investors for your continued support. Operator, you may now disconnect.

Ladies and gentlemen, that concludes today's conference call. Thank you for your participation. You may now disconnect.